Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading ...

In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and ...

Your skin is constantly renewing itself. In healthy skin, new cells are made deep in the epidermis. They slowly move toward ...

A new retrospective cohort study examines the risk of new-onset metabolic comorbidities in Hispanic and Latino patients with ...

Recently approved for moderate to severe psoriasis, the oral IL-23 inhibitor icotrokinra has demonstrated strong efficacy for ...

Johnson & Johnson recently reported new two-year Phase 3 ICONIC-TOTAL data showing its oral peptide ICOTYDE® (icotrokinra) ...

Takeda Pharmaceutical (TSE:4502) has put its psoriasis pipeline in the spotlight after new Phase 3 LATITUDE data showed that ...

If you were around and eating hot dogs in the 70s, you may have seen this incredible (and perhaps sadistic) device used to cook hot dogs via electricity. Aerating your lawn allows nutrients, water, ...

NPF begins a global push to unearth and address the remaining milestones on the path to a cure for psoriasis and ...

Psoriasis affects roughly two to three percent of people worldwide, producing the red, scaly, thickened skin patches that define the disease and, in many patients, paving the way for comorbidities ...

Brodalumab maintains clinical control among adults treated for moderate-to-severe plaque psoriasis, a study reports.